This is after a re-evaluation by The National Institute for Health and Care Excellence (NICE), which has issued a Final Appraisal Document for the use of MSD’s Prevymis (letermovir) for preventing cytomegalovirus (CMV) reactivation and disease after an allogeneic haematopoietic stem cell transplant (HSCT) within the NHS.
